Skip to main content

GLP-1 News

Curated updates on drug launches, pricing changes, insurance coverage, shortages, and clinical trials.

Drug News 4/16/2026 Eli Lilly Press Releases

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

The ACHIEVE-4 trial, the longest Phase 3 study of Foundayo to date, found the oral GLP-1 was non-inferior to insulin glargine for cardiovascular events and showed a 57% lower risk of all-cause death (HR 0.43). Lilly plans to file for a type 2 diabetes indication by end of Q2 2026.

Read now
Clinical Trials 4/16/2026 Endpoints News

Lilly's obesity pill heads for diabetes filing after heart risk trial

After ACHIEVE-4 showed Foundayo cut major cardiovascular events by 16% versus insulin, Lilly plans to file for a type 2 diabetes indication by end of Q2 2026. A diabetes approval would expand prescribing beyond obesity specialists and open broader insurance coverage for the $149/month oral GLP-1.

Read now
Drug News 4/14/2026 Endpoints News

Updated: FDA asks for data on Lilly's Foundayo to assess heart, liver risks

The FDA has requested post-marketing safety data from Lilly on Foundayo (orforglipron), citing unexpected MACE cases and potential drug-induced liver injury seen during clinical trials. Lilly says the ACHIEVE-4 trial data shows no liver safety signal and a 16% lower risk of major cardiovascular events compared to insulin.

Read now
Drug News 4/13/2026 Eli Lilly Press Releases

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

The FDA approved Foundayo (orforglipron) on April 1, 2026, the first oral GLP-1 with no meal-timing restrictions. Self-pay pricing is $149/month, with a $25/month copay option for commercially insured patients. It's already available at retail pharmacies, LillyDirect, Ro, Amazon Pharmacy, and Weight Watchers Med+.

Read now
Drug News 4/12/2026 Eli Lilly Press Releases

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect

Lilly's Zepbound KwikPen is now available at 70,000+ pharmacies nationwide with self-pay pricing starting at $299/month for the 2.5 mg starter dose, roughly 72% below the $1,086 list price for standard single-dose pens. The KwikPen Savings Card covers doses up to 15 mg at $449/month through December 31, 2026.

Read now
Drug News 4/12/2026 Eli Lilly Press Releases

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

The TOGETHER-PsA trial found that combining Zepbound with Taltz delivered a 31.7% rate of dual response (ACR50 + 10% weight loss) in patients with psoriatic arthritis and obesity, compared to 0.8% on Taltz alone. Two-thirds of PsA patients in the U.S. have obesity, making this combination relevant to a large population.

Read now
Drug News 4/12/2026 STAT News

STAT+: Genetics may shape GLP-1 outcomes, slightly

A 23andMe study of 27,885 GLP-1 users found that a variant in the GLP1R gene accounts for 1.7 to 3.3 extra pounds of weight loss per gene copy, while a GIPR variant predicts nausea specifically on tirzepatide. 23andMe now sells a GLP-1 Medications report through its $299/year Total Health membership.

Read now
Drug News 4/11/2026 Eli Lilly Press Releases

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

Foundayo launched at $149/month self-pay on April 9, 2026 — available the same day at retail pharmacies, through LillyDirect, and via telehealth providers including Ro, Amazon Pharmacy, and Weight Watchers Med+. If you've been sitting on the fence about starting a GLP-1, this is the most accessible on-ramp yet: no needles, no meal timing, 27.3 lbs average weight loss at the top dose, and the broadest same-day launch network of any GLP-1 to date.

Read now
Drug News 4/10/2026 Eli Lilly Press Releases

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

The FDA approved Foundayo (orforglipron) on April 1, 2026 — the first GLP-1 pill with no meal-timing rules — launching at $149/month self-pay, with a $25/month option for commercially insured patients. If you've been avoiding GLP-1s because of injection anxiety or high cost, this is the lowest barrier to entry yet: 27.3 lbs average weight loss at the top dose, no fasting required, and the broadest Medicare access pathway of any obesity drug currently on the market.

Read now
Pricing Updates 4/10/2026 STAT News

STAT+: Pharmalittle: We're reading about cheap generic obesity drugs in India, high demand for estrogen patches and more

India's semaglutide patent expired March 20, 2026, and generic prices immediately crashed to roughly $14–15/month — while the same molecule costs over $1,000/month in the US. Generic semaglutide won't reach US pharmacies until 2033–2037 at the earliest, but Foundayo at $149/month self-pay and Zepbound's KwikPen at $299/month are the closest things to patent-cliff pricing available to you right now.

Read now
Pricing Updates 4/10/2026 Eli Lilly Press Releases

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect

As of April 10, 2026, the free Zepbound savings card — $299/month for the 2.5 mg starter dose, $449/month for maintenance — works at over 70,000 pharmacies including Walgreens, Kroger, Sam's Club, Amazon Pharmacy, and Publix. If you're paying $1,050+ retail for Zepbound at any of these chains right now, stop and enroll at zepbound.lilly.com/savings before your next refill — it takes minutes and saves you $600–$750/month.

Read now
Clinical Trials 4/10/2026 Eli Lilly Press Releases

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

Phase 3b data from TOGETHER-PsA, presented at AAD 2026 in Denver, showed Zepbound plus Taltz hit the combined ACR50 + 10% weight loss endpoint in 31.7% of psoriatic arthritis patients — versus 0.8% on Taltz alone. If you're on a biologic for PsA or psoriasis and have obesity, this peer-reviewed paper (published in *Arthritis & Rheumatology* March 2026) is now the document to bring your rheumatologist when requesting a Zepbound prior authorization.

Read now
Clinical Trials 4/9/2026 STAT News

STAT+: Genetics may shape GLP-1 outcomes, slightly

A 27,885-person study published in *Nature* on April 8, 2026 confirmed your GLP1R gene variant can predict about 3.3 extra pounds of weight loss — real, but not enough to change what your doctor prescribes. Before spending $299/year on 23andMe Total Health expecting it to explain your GLP-1 results, know that dose, diet, and adherence still drive the outcome far more than genetics.

Read now
Drug News 4/9/2026 Endpoints News

Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim

Novo Nordisk's 36-year GLP-1 pioneer Lotte Bjerre Knudsen retired in April 2026, the same week obesity specialist Sylvia Shubert moved to Boehringer Ingelheim as SVP of obesity and liver health. Neither departure affects what's in your pharmacy today — but Boehringer's Phase 3 survodutide data, expected H1 2026, could be your first look at a serious third competitor in the GLP-1 weight-loss space.

Read now
Drug News 4/9/2026 STAT News

STAT+: Pharmalittle: We're reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more

PhRMA CEO Steve Ubl announced he'll leave by end of 2026 — his successor inherits a drug class retailing above $1,000/month that costs $10–30 to manufacture, with a Medicare GLP-1 Bridge program launching July 2026 at $245/month. If you're on Medicare and use a GLP-1 for diabetes or cardiovascular risk, check CMS.gov starting July 1 — you may have a new, cheaper access pathway your plan hasn't told you about.

Read now
Drug News 4/9/2026 Endpoints News

Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option

On April 9, 2026, the EMA approved a Wegovy logistics update allowing delivery at up to 30°C for 48 hours — making it the first GLP-1 weight-loss drug in the EU cleared for standard parcel delivery without refrigerated transport. If a Wegovy pen arrives warm after a normal shipping delay, the drug's actual temperature tolerance is higher than most patients assume; your home storage rules haven't changed.

Read now